Endoscopy Unit, Humanitas Clinical and Research Center, RCCS, Milano, Italy.
Department of Biomedical Sciences, Humanitas University, Milan, Italy.
Am J Gastroenterol. 2021 Sep 1;116(9):1853-1858. doi: 10.14309/ajg.0000000000001356.
Multiple therapeutic modalities including surgery and rigid and flexible endoscopy have been adopted to manage Zenker's diverticulum (ZD). Minimally invasive flexible endoscopic septotomy (FES) techniques have been increasingly favored over the past 20 years; however, long-term data are still scanty. The aim of this study is to evaluate early and long-term outcomes of FES for naive ZD in a single-center setting.
From 2010 to 2017, ZD patients treated with FES were included in a prospectively maintained database (NCT03948438). Those who had already been treated surgically or endoscopically were excluded from the analysis. The Dakkak and Bennett dysphagia scale was used to rate the dysphagia. Persistent complete or near-complete resolution of symptoms (Dakkak and Bennett 0 or 1) was defined as clinical success. Postprocedural adverse events were reported according to ASGE lexicon.
Overall, 256 consecutive patients were treated. Mean pouch size was 29.8 ± 11.3 mm. The procedure was successfully completed in all scheduled patients, with an early clinical success of 96.1%. Adverse events occurred in 3.5% (9/256) of patients. Eight of them were mild/moderate with no fatal events, whereas one patient required surgery. Recurrences occurred in 31.3% (80/256) of treated patients after a mean time of 9 ± 3 months and 95% of recurrences were treated by a second FES. At an average follow-up of 5.5 years, 95.3% of patients were asymptomatic after a mean number of 1.3 procedures.
FES is a safe and effective treatment modality for patients with ZD. Recurrence rate is significant; however, endoscopic reintervention is associated with long-term relief of dysphagia.
多种治疗方法,包括手术、硬性和软性内镜检查,已被用于治疗Zenker 憩室(ZD)。在过去的 20 年中,微创软性内镜隔切开术(FES)技术越来越受到青睐;然而,长期数据仍然很少。本研究的目的是在单中心环境中评估 FES 治疗初发性 ZD 的早期和长期结果。
从 2010 年到 2017 年,接受 FES 治疗的 ZD 患者被纳入一个前瞻性维护的数据库(NCT03948438)。那些已经接受过手术或内镜治疗的患者被排除在分析之外。Dakkak 和 Bennett 吞咽困难量表用于评估吞咽困难。持续完全或近乎完全缓解症状(Dakkak 和 Bennett 0 或 1)定义为临床成功。根据 ASGE 词汇表报告术后不良事件。
总体而言,256 例连续患者接受了治疗。平均憩室大小为 29.8 ± 11.3mm。所有预定患者均成功完成了手术,早期临床成功率为 96.1%。3.5%(9/256)的患者出现了不良事件。其中 8 例为轻度/中度,无致命事件,而 1 例患者需要手术。在平均 9 ± 3 个月后,256 例治疗患者中有 31.3%(80/256)出现复发,95%的复发患者接受了第二次 FES 治疗。在平均 5.5 年的随访中,在平均 1.3 次治疗后,95.3%的患者无症状。
FES 是治疗 ZD 患者的一种安全有效的治疗方法。复发率很高;然而,内镜再干预与长期缓解吞咽困难有关。